Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383469 | 1.00 | AR (0.56) | ARCYP17A1ATRCA12CA1 | |
| SCHEMBL6383413 | 0.84 | SORT1 (0.50) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL16055308 | 0.83 | SMARCA2 (0.57) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL1501665 | 0.83 | SMARCA2 (0.57) | ARCYP17A1ATRCA12CA1 | |
| SCHEMBL30293080 | 0.83 | SMARCA2 (0.57) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL9376173 | 0.82 | MAP4K4 (0.49) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL29530078 | 0.81 | CYP17A1 (0.46) | ARCYP17A1ATRCA12CA1 | |
| SCHEMBL4597222 | 0.81 | CYP17A1 (0.46) | ARCYP17A1ATRCA12CA1 | |
| SCHEMBL15972202 | 0.81 | AR (0.45) | ARCYP17A1ATRCA12CA1 | |
| SCHEMBL19513017 | 0.81 | CYP17A1 (0.43) | ARCYP17A1ATRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585260-A | Heterocyclic compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-115803325-B | EGFR inhibitor and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024041613-A1 | HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2024-02-29 | — | — | WO | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
| CN-1252068-C | Heteroaryl derivatives as superior ligands for the nociceptin receptor ORL-1 | SCHERING CORP (US) | 2006-04-19 | — | — | CN | disclosed |
| EP-1442036-B1 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORP (US) | 2006-01-11 | — | — | EP | disclosed |
| CN-1582288-A | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORP (US) | 2005-02-16 | — | — | CN | disclosed |
| EP-1442036-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6727254-B2 | 8-(BIS-(PHENYL) METHYL)-3-HETEROARYL-8-AZABICYCLO-(3.2.1)OCTAN-3-OLS AND DERIVATIVES, USEFUL IN TREATING PAIN, ANXIETY, COUGH, ASTHMA, DEPRESION AND ALCOHOL ABUSE | SCHERING CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003039469-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | AR 4768/4885CYP17A1 1473/4885ATR 1709/4885 |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | AR 427/4885CYP17A1 147/4885ATR 2895/4885 |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | AR 611/4885CYP17A1 1471/4885ATR 492/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | AR 3557/4885CYP17A1 4501/4885ATR 3830/4885 |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OPRK1 | AR 922/4885CYP17A1 1359/4885ATR 4684/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | AR 3557/4885CYP17A1 4501/4885ATR 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.